Apollo Hospitals is committed to translating research into clinical outcomes for patient benefit. With this aspiration, Apollo Hospitals recently incubated and launched Sapien Biosciences within AHERF’s facility in Hyderabad.
Sapien Biosciences is mandated to and is in process of creating a world class bio-bank comprising of high-quality ethically-consented human tissues and its associated data in a state-of-the-art, proprietary database. This shall greatly facilitate the discovery of new treatments and the new/known therapeutics for national and international investigators.
Sapien shall fulfill our vision of delivering better clinical outcomes through bench-to-bedside innovation by offering personalized medicine services to Apollo Hospitals. The company shall leverage pathological data to develop high-end diagnostics for various diseases and shall also facilitate provision of genetic risk assessment tools and gene-based diagnostic panels for cancer, diabetes and ophthalmology ailments. These developments shall drive transformation from reactive to preventive healthcare management amongst patients.
• Sapien and AHERF have launched its first and novel personalized medicine diagnostic test “myPLATELET” at Apollo Hyderabad. Roll out to other Apollo centers are in progress. The test helps to determine patient’s response to their blood-thinning medication and supports decision-making by the cardiologists to personalize therapy for better outcomes. This is the only test in India that combines both genetic and platelet function response to enable tailored anti-platelet therapy for each patient. In 6 months around 200 diagnostic tests have been undertaken and the same test is likely to be rolled out in other locations.
• Customized myCarDiOTM; personalized genetic risk prediction test for Apollo in partnership with Nutragene. The myCarDiOTM test includes a pre- & post-test genetic counseling during which the patient will be counseled on the test details and their results. The test is also configured to include an optional physician consultation after the post-test genetic counseling. It was launched in Apollo Chennai, Main Hospital, in the early November 2014.
• Apollo Hospitals through Sapien also launched cutting-edge clinical genomic tests from Strand Life Sciences across its hospital network as part of its personalized medicine initiative. The roll-out and integration of these tests into the clinical practice across the Apollo network was facilitated through a partnership between Sapien Biosciences and Strand Life Sciences. The first of such partnerships was with Strand Life sciences to launch a set of clinical genomic tests in oncology, cardiovascular, heritable eye diseases and rare genetic disorders at Apollo Chennai, Hyderabad, Delhi, Bangalore, Kolkata and Bhubaneswar.